At the time, the BCR-ABL tyrosine kinase was the best-credentialed tyrosine kinase target in oncology. A couple of years earlier, I had advised Nick that CML, driven by BCR-ABL kinase activity ...

TERN-701 is an oral allosteric BCR-ABL tyrosine kinase inhibitor (TKI) and is one of the two therapies that Terns plans to focus its resources on this year. The treatment is being evaluated in a ...

5, 6 Given the requirement for dimerization for kinase activation, it is conceivable that the deletion mutants have a dominant-negative effect on the native BCR-ABL by formation of heterodimers ...

The study was designed to evaluate the safety and efficacy of the selective c-Abl tyrosine kinase inhibitor in patients with early Parkinson's disease. The PROSEEK study was a global trial that ...

Sino-American biopharma Ascentage Pharma has announced that olverembatinib has been granted Breakthrough Therapy Designation ...

It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as ...

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved ...